Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (PDTX) MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY MECHANISM
16.1 OVERVIEW
16.2 INPUT MECHANISMS
16.2.1 BY TYPE
16.2.1.1. SCREEN
16.2.1.2. ACCELEROMETER
16.2.1.3. MICROPHONE
16.2.2 BY APPLICATION
16.2.2.1. PATIENT DATA COLLECTION
16.2.2.1.1. MOOD
16.2.2.1.2. COGNITION
16.2.2.1.3. MEMORY
16.2.2.1.4. FAMILIAL RECOGNITION
16.2.2.1.5. CONCENTRATION
16.2.2.1.6. OTHERS
16.2.2.2. DEXTERITY OR STEADINESS MEASUREMENT
16.2.2.2.1. STRETCHING
16.2.2.2.2. RANGE OF MOTION TESTS
16.2.2.2.3. OTHERS
16.2.2.3. AUDIO ANALYSIS
16.2.2.3.1. VOICE QUALITY
16.2.2.3.2. SHAKINESS
16.2.2.3.3. OTHERS
16.3 OUTPUT MECHANISMS
16.3.1 BY TYPE
16.3.1.1. SCREEN
16.3.1.2. CHAT
16.3.1.3. NOTIFICATION
16.3.2 BY APPLICATION
16.3.2.1. CONTENT DELIVERY
16.3.2.1.1. BLOGS
16.3.2.1.2. TIPS
16.3.2.1.3. FAQS
16.3.2.1.4. VIDEOS
16.3.2.1.5. OTHERS
16.3.2.2. PATIENT COMMUNICATION
16.3.2.2.1. PROFESSIONAL COACHING
16.3.2.2.2. PEER-TO-PEER SUPPORT
16.3.2.2.3. OTHERS
16.3.2.3. ADHERENCE PROMPTS
16.3.2.3.1. INACTIVITY
16.3.2.3.2. SLEEP
16.3.2.3.3. DIET
16.3.2.3.4. OTHERS
17 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY TREATMENT
17.1 OVERVIEW
17.2 BY USAGE
17.2.1 MEDICATION AUGMENTATION
17.2.2 MEDICATION REPLACEMENT
17.3 BY TYPE
17.3.1 OUTPATIENT TREATMENT
17.3.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
17.3.1.2. FLUENCY TRANING
17.3.1.3. CONTIGENCY MANAGEMENT
17.3.1.4. CRAVING AND TRIGGER ASSESSMENT
17.3.1.5. TRANSMUCOSAL BUPRENORPHINE
17.3.1.6. OTHERS
17.3.2 MONOTHERAPY
17.3.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
17.3.2.2. COGNITIVE RESTRUCTURING
17.3.2.3. OTHERS
17.3.3 OTHERS
18 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY SOFTWARE
18.1 OVERVIEW
18.2 SOFTWARE FOR RESPIATIORY CONDITIONS
18.3 SOFTWARE FOR MENTAL HEALTH
18.4 SOFTWARE FOR OPIOID USE DISORDER
18.5 SOFTWARE FOR DIABETES
18.6 OTHERS
19 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY SERVICES
19.1 OVERVIEW
19.2 BEHAVIORAL MICROSERVICES
19.2.1 PHYSICAL ACITIVITY
19.2.2 RELAXATION TECHNIQUE
19.2.3 DIET OPTIMIZATION
19.2.4 CONTROLLED BREATHING
19.2.5 TELEMEDICINE
19.2.6 MINDFULNESS TRAINING
19.2.7 OTHERS
19.3 MEDICAL MICROSERVICES
19.3.1 MEDICATION MANAGAMENT SYSTEM
19.3.2 FAGERSTROM TEST
19.3.3 PATIENT HEALTH QUESTIONNAIRE
19.3.4 FINANCIAL SAVING ENGINE
19.3.5 HEALTH RECOVERED ENGINE
19.3.6 MORISKY MEDICATION ADHERENCE SCALE
19.3.7 OTHERS
20 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY APP ACCESSIBILITY
20.1 OVERVIEW
20.2 ANDROID
20.2.1 SMARTPHONE
20.2.2 TABLET
20.3 IOS
20.3.1 SMARTPHONE
20.3.2 TABLET
20.4 WINDOWS
20.4.1 SMARTPHONE
20.4.2 TABLET
21 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY APP TYPE
21.1 OVERVIEW
21.2 NATIVE APPS
21.3 WEB APPS
21.4 HYBRID APPS
22 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY APPLICATION
22.1 OVERVIEW
22.2 SUBSTANCE USE DISORDER (SUD)
22.2.1 BY USAGE
22.2.1.1. MEDICATION AUGMENTATION
22.2.1.2. MEDICATION REPLACEMENT
22.2.2 BY TYPE
22.2.2.1. OUTPATIENT TREATMENT
22.2.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.2.2.1.2. FLUENCY TRANING
22.2.2.1.3. CONTIGENCY MANAGEMENT
22.2.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.2.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.2.2.1.6. OTHERS
22.2.2.2. MONOTHERAPY
22.2.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.2.2.2.2. COGNITIVE RESTRUCTURING
22.2.2.2.3. OTHERS
22.2.2.3. OTHERS
22.3 OPIOID USE DISORDER (OUD)
22.3.1 BY USAGE
22.3.1.1. MEDICATION AUGMENTATION
22.3.1.2. MEDICATION REPLACEMENT
22.3.2 BY TYPE
22.3.2.1. OUTPATIENT TREATMENT
22.3.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.3.2.1.2. FLUENCY TRANING
22.3.2.1.3. CONTIGENCY MANAGEMENT
22.3.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.3.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.3.2.1.6. OTHERS
22.3.2.2. MONOTHERAPY
22.3.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.3.2.2.2. COGNITIVE RESTRUCTURING
22.3.2.2.3. OTHERS
22.3.2.3. OTHERS
22.4 ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)
22.4.1 BY USAGE
22.4.1.1. MEDICATION AUGMENTATION
22.4.1.2. MEDICATION REPLACEMENT
22.4.2 BY TYPE
22.4.2.1. OUTPATIENT TREATMENT
22.4.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.4.2.1.2. FLUENCY TRANING
22.4.2.1.3. CONTIGENCY MANAGEMENT
22.4.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.4.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.4.2.1.6. OTHERS
22.4.2.2. MONOTHERAPY
22.4.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.4.2.2.2. COGNITIVE RESTRUCTURING
22.4.2.2.3. OTHERS
22.5 OTHERSALZHEIMER’S DISEASE
22.5.1 BY USAGE
22.5.1.1. MEDICATION AUGMENTATION
22.5.1.2. MEDICATION REPLACEMENT
22.5.2 BY TYPE
22.5.2.1. OUTPATIENT TREATMENT
22.5.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.5.2.1.2. FLUENCY TRANING
22.5.2.1.3. CONTIGENCY MANAGEMENT
22.5.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.5.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.5.2.1.6. OTHERS
22.5.2.2. MONOTHERAPY
22.5.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.5.2.2.2. COGNITIVE RESTRUCTURING
22.5.2.2.3. OTHERS
22.5.2.3. OTHERS
22.6 MAJOR DEPRESSIVE DISORDER (MDD)
22.6.1 BY USAGE
22.6.1.1. MEDICATION AUGMENTATION
22.6.1.2. MEDICATION REPLACEMENT
22.6.2 BY TYPE
22.6.2.1. OUTPATIENT TREATMENT
22.6.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.6.2.1.2. FLUENCY TRANING
22.6.2.1.3. CONTIGENCY MANAGEMENT
22.6.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.6.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.6.2.1.6. OTHERS
22.6.2.2. MONOTHERAPY
22.6.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.6.2.2.2. COGNITIVE RESTRUCTURING
22.6.2.2.3. OTHERS
22.6.2.3. OTHERS
22.7 INSOMNIA
22.7.1 BY USAGE
22.7.1.1. MEDICATION AUGMENTATION
22.7.1.2. MEDICATION REPLACEMENT
22.7.2 BY TYPE
22.7.2.1. OUTPATIENT TREATMENT
22.7.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.7.2.1.2. FLUENCY TRANING
22.7.2.1.3. CONTIGENCY MANAGEMENT
22.7.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.7.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.7.2.1.6. OTHERS
22.7.2.2. MONOTHERAPY
22.7.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.7.2.2.2. COGNITIVE RESTRUCTURING
22.7.2.2.3. OTHERS
22.7.2.3. OTHERS
22.8 COGNITION
22.8.1 BY USAGE
22.8.1.1. MEDICATION AUGMENTATION
22.8.1.2. MEDICATION REPLACEMENT
22.8.2 BY TYPE
22.8.2.1. OUTPATIENT TREATMENT
22.8.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.8.2.1.2. FLUENCY TRANING
22.8.2.1.3. CONTIGENCY MANAGEMENT
22.8.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.8.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.8.2.1.6. OTHERS
22.8.2.2. MONOTHERAPY
22.8.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.8.2.2.2. COGNITIVE RESTRUCTURING
22.8.2.2.3. OTHERS
22.8.2.3. OTHERS
22.9 EPILEPSY
22.9.1 BY USAGE
22.9.1.1. MEDICATION AUGMENTATION
22.9.1.2. MEDICATION REPLACEMENT
22.9.2 BY TYPE
22.9.2.1. OUTPATIENT TREATMENT
22.9.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.9.2.1.2. FLUENCY TRANING
22.9.2.1.3. CONTIGENCY MANAGEMENT
22.9.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.9.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.9.2.1.6. OTHERS
22.9.2.2. MONOTHERAPY
22.9.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.9.2.2.2. COGNITIVE RESTRUCTURING
22.9.2.2.3. OTHERS
22.9.2.3. OTHERS
22.1 MOVEMENT DISORDER
22.10.1 BY USAGE
22.10.1.1. MEDICATION AUGMENTATION
22.10.1.2. MEDICATION REPLACEMENT
22.10.2 BY TYPE
22.10.2.1. OUTPATIENT TREATMENT
22.10.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.10.2.1.2. FLUENCY TRANING
22.10.2.1.3. CONTIGENCY MANAGEMENT
22.10.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.10.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.10.2.1.6. OTHERS
22.10.2.2. MONOTHERAPY
22.10.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.10.2.2.2. COGNITIVE RESTRUCTURING
22.10.2.2.3. OTHERS
22.10.2.3. OTHERS
22.11 MULTIPLE SCLEROSIS
22.11.1 BY USAGE
22.11.1.1. MEDICATION AUGMENTATION
22.11.1.2. MEDICATION REPLACEMENT
22.11.2 BY TYPE
22.11.2.1. OUTPATIENT TREATMENT
22.11.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.11.2.1.2. FLUENCY TRANING
22.11.2.1.3. CONTIGENCY MANAGEMENT
22.11.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.11.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.11.2.1.6. OTHERS
22.11.2.2. MONOTHERAPY
22.11.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.11.2.2.2. COGNITIVE RESTRUCTURING
22.11.2.2.3. OTHERS
22.11.2.3. OTHERS
22.12 MIGRAINE
22.12.1 BY USAGE
22.12.1.1. MEDICATION AUGMENTATION
22.12.1.2. MEDICATION REPLACEMENT
22.12.2 BY TYPE
22.12.2.1. OUTPATIENT TREATMENT
22.12.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.12.2.1.2. FLUENCY TRANING
22.12.2.1.3. CONTIGENCY MANAGEMENT
22.12.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.12.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.12.2.1.6. OTHERS
22.12.2.2. MONOTHERAPY
22.12.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.12.2.2.2. COGNITIVE RESTRUCTURING
22.12.2.2.3. OTHERS
22.12.2.3. OTHERS
22.13 AUSTISM SPECTRUM DISORDER
22.13.1 BY USAGE
22.13.1.1. MEDICATION AUGMENTATION
22.13.1.2. MEDICATION REPLACEMENT
22.13.2 BY TYPE
22.13.2.1. OUTPATIENT TREATMENT
22.13.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.13.2.1.2. FLUENCY TRANING
22.13.2.1.3. CONTIGENCY MANAGEMENT
22.13.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.13.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.13.2.1.6. OTHERS
22.13.2.2. MONOTHERAPY
22.13.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.13.2.2.2. COGNITIVE RESTRUCTURING
22.13.2.2.3. OTHERS
22.13.2.3. OTHERS
22.14 ONCLOGY
22.14.1 BY USAGE
22.14.1.1. MEDICATION AUGMENTATION
22.14.1.2. MEDICATION REPLACEMENT
22.14.2 BY TYPE
22.14.2.1. OUTPATIENT TREATMENT
22.14.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.14.2.1.2. FLUENCY TRANING
22.14.2.1.3. CONTIGENCY MANAGEMENT
22.14.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.14.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.14.2.1.6. OTHERS
22.14.2.2. MONOTHERAPY
22.14.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.14.2.2.2. COGNITIVE RESTRUCTURING
22.14.2.2.3. OTHERS
22.14.2.3. OTHERS
22.15 INFLAMMATION
22.15.1 BY USAGE
22.15.1.1. MEDICATION AUGMENTATION
22.15.1.2. MEDICATION REPLACEMENT
22.15.2 BY TYPE
22.15.2.1. OUTPATIENT TREATMENT
22.15.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.15.2.1.2. FLUENCY TRANING
22.15.2.1.3. CONTIGENCY MANAGEMENT
22.15.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.15.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.15.2.1.6. OTHERS
22.15.2.2. MONOTHERAPY
22.15.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.15.2.2.2. COGNITIVE RESTRUCTURING
22.15.2.2.3. OTHERS
22.15.2.3. OTHERS
22.16 RESPIRATORY
22.16.1 BY USAGE
22.16.1.1. MEDICATION AUGMENTATION
22.16.1.2. MEDICATION REPLACEMENT
22.16.2 BY TYPE
22.16.2.1. OUTPATIENT TREATMENT
22.16.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.16.2.1.2. FLUENCY TRANING
22.16.2.1.3. CONTIGENCY MANAGEMENT
22.16.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.16.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.16.2.1.6. OTHERS
22.16.2.2. MONOTHERAPY
22.16.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.16.2.2.2. COGNITIVE RESTRUCTURING
22.16.2.2.3. OTHERS
22.16.2.3. OTHERS
22.17 CARDIOVASACULAR
22.17.1 BY USAGE
22.17.1.1. MEDICATION AUGMENTATION
22.17.1.2. MEDICATION REPLACEMENT
22.17.2 BY TYPE
22.17.2.1. OUTPATIENT TREATMENT
22.17.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.17.2.1.2. FLUENCY TRANING
22.17.2.1.3. CONTIGENCY MANAGEMENT
22.17.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.17.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.17.2.1.6. OTHERS
22.17.2.2. MONOTHERAPY
22.17.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.17.2.2.2. COGNITIVE RESTRUCTURING
22.17.2.2.3. OTHERS
22.17.2.3. OTHERS
22.18 PAIN MANAGEMENT
22.18.1 BY USAGE
22.18.1.1. MEDICATION AUGMENTATION
22.18.1.2. MEDICATION REPLACEMENT
22.18.2 BY TYPE
22.18.2.1. OUTPATIENT TREATMENT
22.18.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.18.2.1.2. FLUENCY TRANING
22.18.2.1.3. CONTIGENCY MANAGEMENT
22.18.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.18.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.18.2.1.6. OTHERS
22.18.2.2. MONOTHERAPY
22.18.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.18.2.2.2. COGNITIVE RESTRUCTURING
22.18.2.2.3. OTHERS
22.18.2.3. OTHERS
22.19 METABOLIC CONDITIONS
22.19.1 BY USAGE
22.19.1.1. MEDICATION AUGMENTATION
22.19.1.2. MEDICATION REPLACEMENT
22.19.2 BY TYPE
22.19.2.1. OUTPATIENT TREATMENT
22.19.2.1.1. COGNITIVE BEHAVIORAL THERAPY (CBT)
22.19.2.1.2. FLUENCY TRANING
22.19.2.1.3. CONTIGENCY MANAGEMENT
22.19.2.1.4. CRAVING AND TRIGGER ASSESSMENT
22.19.2.1.5. TRANSMUCOSAL BUPRENORPHINE
22.19.2.1.6. OTHERS
22.19.2.2. MONOTHERAPY
22.19.2.2.1. INSOMNIA-SPECIFIC COGNITIVE BEHAVIORAL THERAPY (CBTI)
22.19.2.2.2. COGNITIVE RESTRUCTURING
22.19.2.2.3. OTHERS
22.19.2.3. OTHERS
22.2 OTHERS
23 GLOBAL PRESCRIPTION DIGITAL THERAPEUTICS (DTX) MARKET, BY PATIENTS
23.1 OVERVIEW
23.2 CHILDREN
23.3 ADULTS
24 GLOBAL CELL ANALYSIS MARKET, BY GEOGRAPHY
GLOBAL CELL ANALYSIS MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 FRANCE
24.2.3 U.K.
24.2.4 ITALY
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 TURKEY
24.2.8 BELGIUM
24.2.9 NETHERLANDS
24.2.10 SWITZERLAND
24.2.11 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 AUSTRALIA
24.3.6 SINGAPORE
24.3.7 THAILAND
24.3.8 MALAYSIA
24.3.9 INDONESIA
24.3.10 PHILIPPINES
24.3.11 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 PERU
24.4.4 CHILE
24.4.5 COLOMBIA
24.4.6 VENEZUELA
24.4.7 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 SAUDI ARABIA
24.5.3 UAE
24.5.4 EGYPT
24.5.5 ISRAEL
24.5.6 REST OF MIDDLE EAST AND AFRICA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL CELL ANALYSIS MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL CELL ANALYSIS MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL CELL ANALYSIS MARKET, COMPANY PROFILE
27.1 PEAR THERAPEUTICS, INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPEMENTS
27.2 AKILI INTERACTIVE LABS, INC.
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPEMENTS
27.3 CLICK THERAPEUTICS, INC.
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPEMENTS
27.4 BETTER THERAPEUTICS, LLC
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPEMENTS
27.5 XEALTH
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPEMENTS
27.6 KAIA HEALTH
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPEMENTS
27.7 OMADA HEALTH, INC.
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPEMENTS
27.8 WELLDOC
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPEMENTS
27.9 VOLUNTIS
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPEMENTS
27.1 SOLERA NETWORK
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPEMENTS
27.11 2MORROW INC.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPEMENTS
27.12 GAIA
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPEMENTS
27.13 RESMED
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPEMENTS
27.14 DTHERA SCIENCES
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPEMENTS
27.15 SAMSUNG
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPEMENTS
27.16 BIGHEALTH
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPEMENTS
27.17 PROPELLER HEALTH
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPEMENTS
27.18 F. HOFFMANN-LA ROCHE LTD
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPEMENTS
27.19 LIMBIX HEALTH, INC
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPEMENTS
27.2 NUVOAIR AB
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPEMENTS
27.21 ALTRAN
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPEMENTS
27.22 SENSYNE HEALTH PLC
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPEMENTS
27.23 BIOFOURMIS
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPEMENTS
27.24 SMARTPATIENT GMBH
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPEMENTS
28 CONCLUSION
29 QUESTIONNAIRE
30 ABOUT DATA BRIDGE MARKET RESEARCH
